Treatment allocation strategies for umbrella trials in the presence of multiple biomarkers: A comparison of methods

*Pharmaceutical Statistics* 2021; doi:10.1002/pst.2119

Statistical consideration when adding new arms to ongoing clinical trials: The potentials and the caveats

*Trials* 2021; 22:203

Mentalization for Offending Adult Males (MOAM): Study protocol for a randomized controlled trial to evaluate mentalization-based treatment for antisocial personality disorder in male offenders on community probation

*Trials* 2020; 21:1001

PSU4 Value of information for adaptive trials: Proof of concept study in multi-arm multi-stage trials of interventions for the prevention of surgical site infections

*Value in Health* 2020; 23(S2):S738

Ensuring that COVID-19 research is inclusive: Guidance from the NIHR INCLUDE project

*BMJ Open* 2020; 10(11):e043634

Innovative trial approaches in immune-mediated inflammatory diseases: Current use and future potential

DOI: 10.21203/rs.3.rs-63613/v1

Efficient analysis of time-to-event endpoints when the event involves a continuous variable crossing a threshold

*Journal of Statistical Planning and Inference* 2020; 208:119-29

Controlling type I error rates in multi-arm clinical trials: A case for the false discovery rate

*Pharmaceutical Statistics* 2020

Increasing power in the analysis of responder endpoints in rheumatology: a software tutorial

*medRxiv* 2020

Developing and testing high-efficacy patient subgroups within a clinical trial using risk scores

*Statistics in Medicine* 2020; 39(24):3285-3298